

# Symposium BAU – QoC Board

*Informed Consent:*

*From a Patient's View*

Louis Denis

US TOO – Europa Uomo

# Health Care Stakeholders

Health Authorities

Insurance: Public – Private

Professionals: Clinic – Research  
Public – Private

Industry: Pharma – Technology

Cancer Leagues – Consumers

Patients

# Our View on Management

- Optimal Medical Treatment

Evidence/Conventional/Conscious based  
Multiprofessional

- Patient-centered Care

Shared care, broad support  
Holistic, mutual respect

# The 'confused' Patient

Overload information  
(professionals, media, friends)

Outcomes  
Statistics



The medical labyrinth

Loss of personality

Evidence Based, Guidelines,  
Nomograms

# Patient's Expectations

- Efficacy, efficiency from quality care
- Correct, relevant information, education on side-effects
- Advice, support, patience and empathy in decision making
- Truth and transparency

## Patients Needs

- First the patient then the cancer with emphasis on individual treatment
- If the ‘colloque singulier’ is lost in technology replace it by one steady, assigned member of the team
- Share relevant info with patients and extramuros

# Ultimate Goals of QoC

Define 'State of the Art' treatment

Guarantee 'Good Medical Practice'

Identify ineffective/redundant treatment

Promote rapid access to treatment

Translate research in clinical practice

# The Patient as Partner

A well informed and prepared patient has the unique experience of the disease.

He can become an excellent partner in the subsequent chronic phase of the disease after the initial acute phase of diagnosis and primary treatment.



Transparency, correct  
info/education and truthfull reports  
are the best option

- Redefine doctor (team) – patient dialogue
- Support shared (discussed) decision making
- Patience and outcomes are fundamental
- Prostate unit centres as an option

# Informed Consent: a safety Net

- An integral part of management to protect doctor and patient
- Is an updates, clear and comprehensive document (contract) to describe the treatment options
- Should be signed after a discussion on the contents (read and approved)
- Compare with product drug information (cardio aspirin – Kawasaki syndrome)